New Clues to Men’s Cancer Risk; Exercise and Chemo; GSK Pushes Back on Ranitidine

New clues to why men develop cancer more often than women. (U.S. News & World Report)

Dutch oncologists and surgeons performed the first mandibular implant using a titanium mandible made from 3D images of a patient with head and neck cancer. (Netherlands Cancer Institute)

New recommendations for determining eligibility for clinical trials in lung cancer could improve patient access to trials. (UT Southwestern, JAMA Oncology)

Targeting BCL-2 expression has shown promise for overcoming resistance to CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (Penn Medicine, Cancer Discovery)

Two NCI-funded studies will investigate whether physical activity can reduce chemotherapy toxicity and improve its effectiveness. (Pennington Biomedical Research Center at LSU)

The first-ever randomized trial of CAR T-cell therapy for multiple myeloma showed that the B-cell maturation antigen-targeted therapy idecabtagene vicleucel (Abecma) significantly improved progression-free survival versus standard therapy, Bristol Myers Squibb and 2seventy bio announced.

Daiichi Sankyo and AstraZeneca announced FDA approval of trastuzumab deruxtecan (Enhertu) for HER2-positive unresectable/metastatic non-small cell lung cancer.

Smoking-associated cancer deaths in 2019 were associated with 2 million lost years of life and $21 billion in lost earnings, according to a study by the American Cancer Society.

The FDA granted regular approval to capmatinib (Tabrecta) for metastatic non-small cell lung cancer associated with MET exon 14 skipping.

Bayer announced FDA approval of darolutamide (Nubeqa) plus docetaxel for metastatic hormone-sensitive prostate cancer.

Responding to “speculative commentary” related to pending litigation in the United States, GlaxoSmithKline (GSK) issued a statement asserting that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients.”